View Pages
JB Hunt, GH Research, Abbott: Q2 Beats and Abbott Raises 2026 Profit Guidance
JB Hunt rises on intermodal progress and Q2 EPS beat. GH Research gains on psychedelic sector interest. Abbott jumps 14% after raising 2026 adjusted EPS guidance to $5.45–$5.60.
Editorial companion
What stands out
Abbott Laboratories surprised markets by raising 2026 profit guidance to $5.45, $5.60 a share, sending the stock up about 14% on the Bloomberg Stock Movers feed. The clip matters because it shows how a single guidance bump can dominate headlines even when underlying sales momentum is weak. Abbott’s average revenue growth has been only 0.7% while average net income rose 21.8%, so the pop reflects profit improvement more than top-line acceleration. For disciplined investors this is a reminder to look past the headline move.
Bullish Gator Snapshot
Current ratings and signals
Abbott Laboratories (ABT)
Neutral
ABT rates Neutral overall. The fundamental read is neutral: the company passes 4 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 4.95); revenue is growing about 0.7% per year; net income is growing about 21.8% per year. The technical picture is neutral: price is 2.3% above the 200-day moving average; 1.2% below the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 72/100), based on 6 news articles and 2 qualified videos from recent coverage.